About: Obinutuzumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Obinutuzumab Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML). (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5E0D-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5E0E-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# FDA label. (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	The half life of obinutuzumab is 28.4 days. (en)
http://linked.open...ugbank/indication	Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. (en)
sameAs	Obinutuzumab
Title	Obinutuzumab (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/drugbank/DB08935 http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/kegg-drug/D09321 http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/national-drug-code-directory/50242-070-01 http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/wikipedia/Obinutuzumab
http://linked.open...mechanismOfAction	In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies. (en)
http://linked.open...outeOfElimination	The route of elimination of obinutuzumab was not indicated (FDA label). (en)
http://linked.open.../drugbank/synonym	Afutuzumab (en)
http://linked.open...drugbank/toxicity	The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment. (en)
http://linked.open...umeOfDistribution	Obinutuzumab has a volume of distribution of about 3.8 L. (en)
http://linked.open...k/foodInteraction	Echinacea: diminished therapeutic effect of immunosuppressants (en)
http://linked.open...nk/proteinBinding	Obinutuzumab does not bind to plasma proteins. (en)
http://linked.open...ynthesisReference	Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96. (en)
foaf:page	http://www.drugs.com/gazyva.html http://www.rxlist.com/gazyva-drug.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5E11-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5E10-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5E0F-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Obinutuzumab
http://linked.open...ugbank/absorption	Obinutuzumab is administered intravenously, so its absorption is 100%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	949142-50-1 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	The clearance of obinutuzumab is 0.09L/day. (en)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software